Motoharu Shibusawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9429412/publications.pdf

Version: 2024-02-01

2258059 1474206 21 80 3 9 citations g-index h-index papers 21 21 21 87 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Prognostic impact of <i>CEBPA</i> bZIP domain mutation in acute myeloid leukemia. Blood Advances, 2022, 6, 238-247.	5.2	61
2	Varicella Infection Complicated by Marked Thrombocytopenia. Japanese Journal of Infectious Diseases, 2014, 67, 292-294.	1.2	4
3	Ruxolitinib for Acute Graft-versus-Host Disease. New England Journal of Medicine, 2020, 383, 500-502.	27.0	3
4	Plasma cell leukaemia presenting as flower-shaped plasma cells mimicking adult T-cell leukaemia or lymphoma. Lancet Haematology,the, 2020, 7, e270.	4.6	3
5	A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib. Investigational New Drugs, 2021, 39, 1457-1459.	2.6	3
6	NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. International Journal of Hematology, 2022, , 1.	1.6	2
7	Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies. Journal of Clinical Oncology, 2020, 38, 4223-4224.	1.6	1
8	Chronic myelogenous leukaemia with a p53 mutation demonstrated neutrophilic granulocytes with nuclear hypolobation (pseudo-Pelger-H \tilde{A}^{1} /4et anomaly) and hypogranulation in the peripheral blood smear. BMJ Case Reports, 2018, 2018, bcr-2017-221907.	0.5	1
9	Evans Syndrome Associated with Hematological Malignancies: A Literature Review. Medical Research Archives, 2021, 9, .	0.2	1
10	Response-Adapted Postinduction Strategy in Follicular Lymphoma. Journal of Clinical Oncology, 2022, , JCO2102818.	1.6	1
11	Subcutaneous versus intravenous daratumumab in multiple myeloma. Lancet Haematology,the, 2020, 7, e558.	4.6	0
12	Long-term efficacy and safety of ruxolitinib in polycythaemia vera. Lancet Haematology,the, 2020, 7, e505-e506.	4.6	0
13	Survival outcomes for extranodal natural-killer T-cell lymphoma. Lancet Haematology,the, 2020, 7, e442.	4.6	0
14	Acute Myelogenous Leukemia with the $t(7;7)(p15;p22)$ Translocation, a Novel Simple Variant of $t(7;11)(p15;p15)$ Translocation: First Description. Case Reports in Hematology, 2021, 2021, 1-4.	0.4	0
15	Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet, The, 2021, 397, 1621.	13.7	0
16	PET-guided omission of radiotherapy in Hodgkin lymphoma. Lancet Oncology, The, 2021, 22, e181.	10.7	0
17	Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 326, 359.	7.4	0
18	Oral Azacitidine in Patients With Myelodysplastic Syndrome. Journal of Clinical Oncology, 2021, 39, 3091-3092.	1.6	0

#	Article	IF	CITATIONS
19	Large Intestine Infarction due to Mucormycosis Complicated with Acute Myeloid Leukemia. Case Report. American Journal of Infectious Diseases and Microbiology, 2014, 2, 51-54.	0.2	0
20	Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report. American Journal of Internal Medicine, 2015, 3, 156.	0.1	0
21	Multiple Septic Emboli in the Skin, Lungs, and Brain due to Corynebacterium Striatum Bacteremia in a Patient with Acute Myelogenous Leukemia. American Journal of Medical Case Reports, 2018, 6, 241-246.	0.2	0